The treatment of sporadic versus MEN1-related pituitary adenomas

Journal of Internal Medicine

Volumn 253, Issue 6, 2003, Pages 599-605

  Beckers, A ^a,b   Betea, D ^a   Valdes Socin, H ^a   Stevenaert, A ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Acromegaly; Multiple endocrine neoplasia type I syndrome; Pituitary adenomas

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; PEGVISOMANT; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CONFERENCE PAPER; CUSHING DISEASE; GENE MUTATION; HUMAN; HYPOPHYSIS ADENOMA; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; PROLACTINOMA; TRANSSPHENOIDAL SURGERY; TUMOR SUPPRESSOR GENE;

ACROMEGALY; ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; OCTREOTIDE; PANCREATIC NEOPLASMS; PATIENT SELECTION; PEPTIDES, CYCLIC; PROLACTINOMA; SOMATOSTATIN;

EID: 0038357688     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01164.x     Document Type: Conference Paper

References (73)

1. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954; 16: 363-71.
2. Teh BT. Thymic carcinoids in multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 501-4.
3. Teh BT. Grimmond S, Shepherd J. Larsson C, Hayward N. Multiple endocrine neoplasia type I: clinical syndrome to molecular genetics. Aust N Z J Surg 1995; 65: 708-13.
4. Nord B, Platz A. Smoczynski K et al. Malignant melanoma in patients with multiple endocrine neoplasia type 1 and involvement of the MEN1 gene in sporadic melanoma. Int J Cancer 2000; 87: 463-7.
5. Giraud S, Choplin H, Teh BT et al. A large multiple endocrine neoplasia type 1 family with clinical expression suggestive of anticipation. J Clin Endocrinol Metab 1997: 82: 3487-92.
6. Darling TN, Skarulis MC, Steinberg SM, Marx SJ. Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997; 133: 853-7.
7. Beckers A, Abs R, Willems PJ et al. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. J Clin Endocrinol Metab 1992; 75: 564-70.
8. Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-7.
9. Lemmens I. VandeVen WJ, Kas K et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997; 6: 1177-83.
10. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001: 1: 157-62.
11. Colao A. Annunziato L. Lombardi G. Treatment of prolactinomas. Ann Med 1998; 30: 452-9.
12. Colao A, Di Sarno A, Marzullo P et al. New medical approaches in pituitary adenomas. Horm Res 2000; 53 Suppl 3: 76-87.
13. Verhelst J, Abs R, Maiter D et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84: 2518-22.
14. Di Sarno A, Landi ML, Marzullo P et al. The effect of quinagolide and Cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000: 53: 53-60.
15. Pinzone JJ, Katznelson L, Danila DC. Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 2000: 85: 3053-7.
16. Webster J, Piscitelli G, Polli A. Ferrari CI. Ismail I, Scanlon MF. A comparison of Cabergoline and Bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994: 6: 904-9.
17. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res 1992: 38: 84-9.
18. Morange I, Barlier A, Pellegrini I, Brue T. Enjalbert A. Jaquet P. Prolactinomas resistant to Bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996; 135: 413-20.
19. Amar AP. Couldwell WT. Chen JC. Weiss MH. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 2002; 97: 307-14.
20. Losa M, Mortini P, Barzaghi R, Gioia L. Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002; 87: 3180-6.
21. Jane JA Jr, Laws ER. Surgical management of pituitary adenomas. Jr Singapore Med J 2002; 43: 318-23.
22. Pollock BE. Nippoldt TB. Stafford SL, Foote RL. Abboud CF. Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg 2002: 97: 525-30.
23. Colin P, Scavarda D. Delemer B et al. Fractionated stereotactic radiotherapy: results in hypophyseal adenomas, acoustic neurinomas, and meningiomas of the cavernous sinus. Cancer Radiother 1998: 2: 207-14.
24. Shimon I. Yan X. Taylor JE, Weiss MH. Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997: 100: 2386-92.
25. Hofland LJ. De Herder WW. Visser-Wisselaar HA et al. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors. J Clin Endocrinol Metab 1997; 82: 3011-8.
26. Saveanu A. Gunz G, Dufour H et al. Bim-23244. a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001: 86: 140-5.
27. Bruns C, Lewis I. Briner U, Meno-Tetang G. Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002: 146: 707-16.
28. Petrossians P, de Herder W. Kwekkeboom D. Lamberigts G. Stevenaert A, Beckers A. Malignant prolactinoma discovered by D2 receptor imaging. J Clin Endocrinol Metab 2000; 85: 398-401.
29. Stevenaert A. Beckers A. Presurgical Octreotide treatment in acromegaly. Metabolism 1996; 45(8 Suppl 1): 72-4.
30. Colao A, Ferone D, Cappabianca P et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997; 82: 3308-14.
31. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002; 87: 4142-6.
32. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87: 3013-8.
33. Caron P, Beckers A, Cullen DR et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002: 87: 99-104.
34. Melmed S, Casanueva FF. Cavagnini F et al. Guidelines for acromegaly management. Acromegaly Treatment Consensus Workshop Participants. J Clin Endocrinol Metab 2002: 87: 4054-8.
35. Beckers A. Pituitary Adenornas. CD-Rom. 2nd edn. GraphMed. Liège, Belgium. 2002.
36. Barkan AL, Lloyd RV. Chandler WF et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67: 1040-8.
37. Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 1999: 84: 3551-5.
38. Freda PU, Wardlaw SL. Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998: 89: 353-8.
39. Newman CB. Melmed S. George A et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998: 83: 3034-40.
40. Bevan JS. Atkin SL. Atkinson AB et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002: 87: 4554-63.
41. Lamberts SW. Zweens M. Klijn JG. van Vroonhoven CC. Stefanko SZ. Del Pozo E. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxf) 1986: 25: 201-12.
42. Colao A. Ferone D. Marzullo P et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997: 82: 518-23.
43. Marzullo P, Ferone D. Di Somma C et al. Efficacy of combined treatment with lanreotide and Cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999: 1: 115-20.
44. Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000: 342: 1171-7.
45. van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358: 1754-9.
46. Parkinson C, Drake WM. Roberts ME, Meeran K, Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002; 87: 1797-804.
47. Morange-Ramos I, Regis J, Dufour H et al. Acta Gamma-knife surgery for secreting pituitary adenomas. Neurochir (Wien) 1998: 140: 437-43.
48. Chanson P. Petrossians P. Les adénomes hypophysaires non fonctionnelles. John Libbey Eurotext Edition. Paris. 1998.
49. Stevenaert A, Perrin G, Martin D, Beckers A. Cushing's disease and corticotrophic adenoma: results of pituitary microsurgery. Neurochirurgie 2002; 48: 234-65.
50. Martin D, Valdes-Socin H, Beckers A, Stevenaert A. Cushing's disease and corticotroph adenoma: anterior pituitary function before and after trans-sphenoidal microsurgery. Neurochirurgie 2002: 48: 226-33.
51. Beckers A, Stevenaert A, Pirens G, Flandroy P. Sulon J, Hennen G. Cyclical Cushing's disease and its successful control under sodium valproate. J Endocrinol Invest 1990: 13: 923-9.
52. Verhelst JA, Trainer PJ, Howlett TA et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991; 35: 169-78.
53. Scheithauer BW. Laws ER Jr, Kovacs K, Horvath E, Randall RV, Carney JA. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol 1987; 4: 205-11.
54. O'Brien T, O'Riordan DS, Gharib H. Scheithauer BW, Ebersold MJ, van Heerden JA. Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. Neurosurgery 1996: 39: 273-8, discussion 278-9.
55. Farid RF. Buehler S, Russell NA, Maroun FB, Allerdice P, Smyth HS. Prolactinomas in familial multiple endocrine neoplasia syndrome type, Relationship to HLA and carcinoid tumors. Am J Med 1980; 69: 874-80.
56. Burgess JR, Shepherd JJ. Parameswaran V, Hoffman L, Greenaway TM. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. J Clin Endocrinol Metab 1996; 81: 1841-5.
57. Petty EM, Green JS, Marx SJ, Taggart RT, Farid N. Bale AE. Mapping the gene for hereditary hyperparathyroidism and prolactinoma (MEN1Burin) to chromosome 11q: evidence for a founder effect in patients from Newfoundland. Am J Hum Genet 1994; 54: 1060-6.
58. Olufemi SE. Green JS. Manickam P et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum Murat 1998: 11: 264-9.
59. Burgess JR, Harle RA. Tucker P et al. Adrenal lesions in a large kindred with multiple endocrine neoplasia type 1. Arch Surg 1996: 131: 699-702.
60. Burgess JR, Shepherd JJ, Parameswaran V. Hoffman L, Greenaway TM. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 1996; 81: 2642-6.
61. Burgess JR, Greenaway TM. Shepherd JJ. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 465-70.
62. Burgess JR, Nord B, David R et al. Phenotype and phenocopy: the relationship between genotype and clinical phenotype in a single large family with multiple endocrine neoplasia type 1 (MEN 1). Clin Endocrinol (Oxf) 2000: 53: 205-11.
63. Verges B, Boureille F, Goudet P et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002; 87: 457-65.
64. Brandi ML. Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86: 5658-71.
65. Marx SJ, Nieman LK. Aggressive pituitary tumors in MEN1: do they refute the two-hit model of tumorigenesis? J Clin Endocrinol Metab 2002: 87: 453-6.
66. Marx SJ, Agarwal SK, Kester MB et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res 1999; 54: 397-438, discussion 438-9.
67. Schussheim DH, Skarulis MC. Agarwal SK et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001; 12: 173-8.
68. Stratakis CA, Schussheim DH, Freedman SM et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2000; 85: 4776-80.
69. Beckers A, Abs R, Reyniers E et al. Variable regions of chromosome 11 loss in different pathological tissues of a patient with the multiple endocrine neoplasia type I syndrome. J Clin Endocrinol Metab 1994: 79: 1498-502.
70. Zhuang Z, Ezzat SZ. Vortmeyer AO et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res 1997; 57: 5446-51.
71. Prezant TR, Levine J, Melmed S. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab 1998: 83: 1388-91.
72. Poncin J, Stevenaert A, Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur J Endocrinol 1999: 140: 573-6.
73. Poncin J, Abs R, Velkeniers B et al. Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Hum Mutat 1999; 13: 54-60.